Logo

Novartis Reports Histology Data of CFZ533 (iscalimab) in Kidney Transplantation for Extended Survival of Transplanted Organs

Share this

Novartis Reports Histology Data of CFZ533 (iscalimab) in Kidney Transplantation for Extended Survival of Transplanted Organs

Shots:

  • The study involves assessing of calcineurin-free treatment with iscalimab vs tacrolimus to test the durability of transplanted kidney grafts and improve long-term outcomes for kidney transplant patients
  • The study resulted in 60% normal kidney histology@1 year for iscalimab-treated transplant patients with lower chronic allograft damage index (CADI) scores- Presented at American Transplant Congress (ATC) 2019
  • Iscalimab is a mAb that prevents CD40 pathway signaling- further activates CD40+ cell types and is currently evaluated in P-IIb trial (Cirrus I- NCT03663335)

Ref: Novartis | Image: Xtra Shot

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions